Skip to content

Search

A population health approach in education to support children's early development: A Critical Interpretive Synthesis

The results from this review indicate that it would indeed be plausible to adapt the population health approach to sites and schools

Assessing Diversity in Early Childhood Development in the East Asia-Pacific

In all six countries, child development scores increased with age and urban children consistently performed better than rural children

Early developmental risk for subsequent childhood mental disorders in an Australian population cohort

We examined associations between developmental vulnerability profiles determined at the age of 5 years and subsequent childhood mental illness between ages 6 and 13 years in an Australian population cohort.

Prenatal omega-3 LCPUFA and symptoms of allergic disease and sensitization throughout early childhood

Maternal supplementation with 900 mg of ω-3 LCPUFA did not change the progression of IgE-mediated allergic disease symptoms or sensitization

Oxidative stress in early cystic fibrosis lung disease is exacerbated by airway glutathione deficiency

are oxidative stress or glutathione status associated with brochiectasis and whether glutathione deficiency is inherently linked to CF or from oxidative stress

Duration of general anaesthetic exposure in early childhood and long-term language and cognitive ability

Anaesthetic dose causing toxicity in animals has been evaluated, but the relationship between duration of VA exposure and development in children remains vague.

An exposome perspective: Early-life events and immune development in a changing world

Here we review the historical origins of exposome research and define a new concept, the metaexposome

The impact of expanding access to early childhood education services in rural Indonesia.

This article examines the relationship between preschool quality and children’s early development in a sample of over 7900 children enrolled in 578 preschools in rural Indonesia.

Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series

Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.